Novo Nordisk phase 2 trial with amycretin reports
Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeksAmycretin demonstrated statistically significant reductions in HbA1c with up to 89.1% achieving HbA1c levels below 7%Amycretin appeared to…